Corvus Pharmaceuticals Inc.

Clinical-stage biopharma pioneering ITK inhibition as a new approach to immunotherapy across immune diseases and cancer. Lead asset soquelitinib (CPI-818) is an oral, selective ITK inhibitor in a Phase 3 registrational trial for relapsed/refractory peripheral T-cell lymphoma, with a Phase 2 atopic dermatitis trial initiating in 2026 following positive Phase 1 cohort 4 results.